Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2006-07-06 Board/Management Inform…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Immediate report on other matter
Board/Management Information Classification · 100% confidence The document is a short announcement about a managerial change, specifically the departure of the CFO and appointment of a new financial officer. It does not contain financial data, regulatory certifications, or detailed reports. The content fits the category of Board/Management Information (MANG) as it relates to changes in senior management positions.
2006-07-06 Hebrew (modern)
Immediate report on other matter
Board/Management Information Classification · 99% confidence The document is very short (1424 characters) and explicitly states 'Immediate report on other matter' and includes an 'Attached file *ManagerialChange06Jul06_isa.pdf*'. The reference to 'ManagerialChange' strongly suggests a change in management or board composition. Reviewing the definitions, 'Board/Management Information' (MANG) fits this description best. Furthermore, due to its brevity and the nature of announcing an attached file, it aligns with the 'MENU VS MEAL' rule, suggesting it is an announcement rather than the full report itself. However, MANG is a specific category for management changes, which is more precise than the general 'RPA' or 'RNS' fallback, assuming the attached PDF contains the actual management change details.
2006-07-06 English
Investor Presentation 2006
Investor Presentation Classification · 70% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It announces that the company's CEO will present at the Jefferies Life Sciences Conference, including details about the presentation date, time, and webcast information. The document does not contain financial statements or detailed financial analysis, nor does it present full annual or interim reports. It is primarily an announcement of an investor presentation event. Given the content and purpose, the document best fits the category of Investor Presentation (IP). However, since it is an announcement of a future presentation rather than the presentation materials themselves, and the document length is short (3368 characters), it aligns more closely with a Regulatory Filing (RNS) as a general announcement. But considering the specific nature of the announcement about an investor presentation event, the classification as Investor Presentation (IP) is appropriate with moderate confidence.
2006-06-27 English
Immediate report on other matter
Investor Presentation Classification · 90% confidence The document is a short announcement about the company's CEO presenting at a life sciences conference. It includes details about the presentation date, time, and webcast information. There is no financial data, no report attached or referenced as being published, and no regulatory filing or certification content. The document is essentially an investor presentation announcement or event notice. Given the content and length (1954 characters), it fits best as an Investor Presentation (IP) type, as it focuses on a presentation for investors about the company's activities and pipeline.
2006-06-26 Hebrew (modern)
Immediate report on other matter
Report Publication Announcement Classification · 98% confidence The document is very short (1409 characters) and explicitly states 'Immediate report on other matter' and includes a line: 'Attached file 26062006_isa.pdf'. This structure indicates that the document itself is merely an announcement or cover letter informing the recipient that a substantive report (in this case, a PDF) has been published or attached, rather than being the full report content itself. This aligns perfectly with the definition of a Report Publication Announcement (RPA). It is not a specific regulatory form like 10-K, ER, or IR, nor does it detail specific events like dividends (DIV) or director dealings (DIRS). Therefore, RPA is the most appropriate classification based on the 'MENU VS MEAL' rule.
2006-06-26 English
Regulatory Filings 2006
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, XTL Biopharmaceuticals Ltd., providing an update to its 2005 Annual Report on Form 20-F. It discusses an auditor's going concern qualification in the annual report and subsequent financing activities that resolved the concern. The document is a regulatory update rather than the full annual report itself. It references the annual report but does not contain the full financial statements or detailed financial data. The document length is 5536 characters, which is relatively short and consistent with an announcement or update rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements and updates that do not fit other specific categories.
2006-06-07 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.